Related Experiment Video
Updated: Mar 20, 2026
09:14
Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line
Published on: September 28, 2022
4.7K
Development of a Low-Cost Stem-Loop Real-Time Quantification PCR Technique for EBV miRNA Expression Analysis
Massimiliano Bergallo1,2, Chiara Merlino3, Davide Montin4
1Department of Public Health and Pediatric Sciences, Medical School, University of Turin, Turin, Italy. massimiliano.bergallo@unito.it.
Molecular Biotechnology
|June 2, 2016
Summary
Epstein Barr virus (EBV) microRNAs (miRNAs) show potential as biomarkers for EBV-associated diseases. A developed real-time PCR assay detected higher miR-BART22 levels in primary immunodeficiency patients, confirming its utility for disease monitoring.
Area of Science:
- Molecular Biology
- Virology
- Biochemistry
Background:
- MicroRNAs (miRNAs) are crucial regulators of physiological processes and are encoded by various viruses, including Epstein Barr virus (EBV).
- EBV-encoded miRNAs are found in high concentrations in pathologies like Burkitt's lymphoma, Hodgkin disease, and nasopharyngeal carcinoma.
- The stability of these viral miRNAs suggests their potential as biomarkers for EBV-associated diseases.
Purpose of the Study:
- To develop a sensitive and quantitative method for detecting and measuring specific Epstein Barr virus microRNAs (miRNAs).
- To evaluate the utility of these viral miRNAs as potential biomarkers in patient serum samples.
- To analyze miRNA expression profiles in individuals with primary immunodeficiency and healthy controls.
Main Methods:
- Development of a stem-loop real-time PCR assay for the detection and quantification of EBV-specific miRNAs: miR-BART2-5p, miR-BART15, and miR-BART22.
- Analysis of 31 serum samples from patients with primary immunodeficiency, X-linked agammaglobulinemia, and healthy subjects.
- Assessment of assay performance, including dynamic range and sensitivity, for accurate miRNA quantification.
Main Results:
- The developed real-time PCR assay demonstrated a wide dynamic range (10^8-10^2 copies/reaction) and high sensitivity (10^2 copies/reaction).
- Significantly higher levels of miR-BART22 were observed in serum samples from primary immunodeficiency patients compared to other groups and miRNA targets (P < 0.0001).
- The findings highlight specific miRNA expression patterns associated with certain patient cohorts.
Conclusions:
- The developed stem-loop real-time PCR assay is a reliable tool for monitoring Epstein Barr virus (EBV)-associated diseases.
- Serum miR-BART22 levels can serve as a potential biomarker for primary immunodeficiency.
- This assay facilitates the analysis of miRNA expression profiles for diagnostic and prognostic purposes in EBV-related conditions.
